WuXi AppTec and WuXi Biologics Rise Amid US Legislation Targeting Chinese Biotech Companies

Friday, 4 October 2024, 10:00

Biotech companies WuXi AppTec and WuXi Biologics saw significant stock increases in Hong Kong as they strategize divestitures following US legislative scrutiny. This move highlights the ongoing tension between the US and China in the biotech sector, emphasizing a shift in operational focus for these firms. The proposed Biosecure Act poses potential ramifications for targeted Chinese companies.
Scmp
WuXi AppTec and WuXi Biologics Rise Amid US Legislation Targeting Chinese Biotech Companies
Biotech Companies See Surge: WuXi AppTec and WuXi Biologics Respond to US Legislation

WuXi AppTec and WuXi Biologics Rise Amid US Legislation Targeting Chinese Biotech Companies

Biotech companies like WuXi AppTec and WuXi Biologics witnessed sharp share price surges in Hong Kong, each climbing significantly as they maneuver through new US legislation aimed at Chinese firms. This legislative framework has forced these companies to consider divesting certain operations to mitigate risks.

Share Surge Amid Legislative Scrutiny

Shares of WuXi AppTec closed at nearly 12 percent higher, while its subsidiary's stocks rose by 15 percent following reports of potential sales of their cell and gene therapy units. This is in direct response to the proposed Biosecure Act which would limit business engagements with certain Chinese biotech companies.

Divestment Strategies and Market Reactions

  • WuXi Advanced Therapies could see its operations in Philadelphia sold off.
  • Reports indicate WuXi Biologics is exploring interest in its European facilities.
  • Both companies are striving to adhere to the Biosecure Act ahead of its expected passage.

Broader Impacts on the Biotech Sector

The legislative pressures faced by these biotech companies underscore a larger trend affecting Chinese firms amid growing tensions with the US. Li Ge, the notable founder, continues to shape the narrative for WuXi PharmaTech, ensuring the firm adapts to shifting market and regulatory landscapes.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most reliable and up-to-date tech news. Stay informed and elevate your tech expertise effortlessly.

Subscribe